Cardiovascular disease (CVD) often manifests as more than one long-term condition. Multimorbidity, commonly described as the presence of multiple concurrent medical conditions, is more common with age and associated with high mortality, reduced functional status, and increased hospitalisation. It is estimated that by 2035, 17% of UK citizens above sixty-five will have four or more chronic conditions. Multimorbidity comes with complex medication prescribing concerns. Inappropriate polypharmacy often results in non-optimal treatment and patient injury because of adverse effects from multiple medications_._ Treatment cost is also a factor: Based on the results of two studies, patients with 2--3 conditions have between 1.55 and 2.85 times the mean expected total cost of individuals without any comorbidity. Medicines is the most common intervention in healthcare and a key component of all care pathways. Treating multimorbidity is complicated. Different conditions and treatments (medicines) interact in complex ways with unique impacts and evidence shows treating patients in accordance with evidence-based medicine guidelines is effective. Reasons for suboptimal treatment include _inter alia_ clinician lack of awareness and implementation of evidence-based guidelines, time, and resources constraints. Guidelines are often lengthy and complex and rely on clinician's cognitive abilities and recall. The development of digital prescribing Clinical Decision Support Systems (CDSS) -- based on guidelines and developed to optimise polypharmacy - has been identified as a key facilitator in busy clinical practice and a step towards precision medicine in polypharmacy. DXS International are developing a novel solution, ExpertCare AI CDSS, that uses artificial intelligence to support health professionals in quickly, accurately, and consistently implementing the guidelines using contextualized information based on the patient's clinical and therapeutic status, including comorbidities. This solution provides the first steps in an attempt to build a commercially viable precision medicine optimisation CDSS -- to be deployed in the clinician workflow and at the point-of-care - that combines comprehensive patient demographic and clinical data to evidence-based treatment considerations in pursuit of precision medicine and optimum medicines treatment outcomes. The first iteration of the solution focuses on cardiovascular disease. Here, the focus is therapeutic management of hypertension together with the condition's most prevalent comorbidities that include diabetes, chronic kidney disease, atrial fibrillation, angina, myocardial infarction, heart failure and hypercholesterolemia. DXS, in partnership with the Eastern AHSN will validate the solutions efficacy and economic benefits during an 18-month long real-world evaluation in clinical settings to generate evidence of the solutions efficacy and clinical value.